biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > CIDP and GBS

<< Previous

Bullboard Posts

Next >>

Comment by prophetoffactzon Dec 10, 2022 9:47pm

109 Views

Post# 35164326

RE:RE:CIDP and GBS

"According to the study, Sars-CoV-2 actually infects retinal cells, especially retinal ganglion cells, but also light-sensitive cells. Furthermore, the researchers show that coronaviruses can also replicate in these cell types. This finding is new and underlines the need to monitor retinal pathologies as a possible consequence of 'Long Covid'."
There is more to SARS-CoV-2 than meets the eye | Max-Planck-Gesellschaft (mpg.de)

<< Previous

Bullboard Posts

Next >>

5 steps to mastering risk management in the stock market